Flinton Capital Management LLC lowered its stake in shares of Elanco Animal Health (NYSE:ELAN) by 34.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,146 shares of the company’s stock after selling 4,794 shares during the quarter. Flinton Capital Management LLC’s holdings in Elanco Animal Health were worth $309,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. Water Island Capital LLC purchased a new stake in Elanco Animal Health during the 1st quarter worth $27,000. Steward Partners Investment Advisory LLC purchased a new stake in Elanco Animal Health during the 2nd quarter worth $32,000. Capital Investment Advisory Services LLC boosted its position in Elanco Animal Health by 1,501.4% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 1,121 shares of the company’s stock worth $36,000 after purchasing an additional 1,051 shares during the period. Valeo Financial Advisors LLC boosted its position in Elanco Animal Health by 376.7% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,430 shares of the company’s stock worth $48,000 after purchasing an additional 1,130 shares during the period. Finally, Citizens Financial Group Inc RI purchased a new stake in Elanco Animal Health during the 1st quarter worth $48,000.
In other Elanco Animal Health news, insider Michael-Bryant Hicks purchased 11,030 shares of the stock in a transaction dated Thursday, August 22nd. The stock was bought at an average price of $26.65 per share, for a total transaction of $293,949.50. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Deborah Turner Kochevar acquired 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were purchased at an average price of $27.95 per share, with a total value of $27,950.00. Insiders have bought a total of 112,780 shares of company stock valued at $3,003,162 over the last ninety days. 0.04% of the stock is owned by insiders.
A number of analysts recently weighed in on ELAN shares. Goldman Sachs Group began coverage on shares of Elanco Animal Health in a research report on Monday, September 9th. They set a “positive” rating for the company. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Elanco Animal Health from a “hold” rating to a “sell” rating in a research note on Friday, September 6th. Bank of America downgraded shares of Elanco Animal Health from a “buy” rating to a “neutral” rating and set a $30.00 price objective for the company. in a research report on Monday, August 26th. UBS Group raised shares of Elanco Animal Health from a “sell” rating to a “neutral” rating and lowered their price objective for the company from $31.00 to $30.00 in a research report on Thursday, August 15th. Finally, Barclays began coverage on shares of Elanco Animal Health in a report on Monday, September 23rd. They issued an “overweight” rating and a $36.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. Elanco Animal Health currently has an average rating of “Hold” and a consensus price target of $33.98.
Shares of ELAN opened at $26.40 on Friday. Elanco Animal Health has a 12 month low of $25.51 and a 12 month high of $36.21. The company’s fifty day moving average is $27.76 and its 200-day moving average is $31.39. The company has a quick ratio of 1.71, a current ratio of 3.07 and a debt-to-equity ratio of 0.45. The firm has a market cap of $9.87 billion and a price-to-earnings ratio of 24.31.
Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, August 13th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.02. The business had revenue of $781.60 million for the quarter, compared to analyst estimates of $781.49 million. Elanco Animal Health had a net margin of 4.69% and a return on equity of 7.83%. Elanco Animal Health’s revenue was up 1.5% compared to the same quarter last year. As a group, research analysts predict that Elanco Animal Health will post 1.08 earnings per share for the current fiscal year.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Featured Article: How do investors use RSI to grade stocks?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.